Less Radical Surgery for Patients with Early-Stage Cervical Cancer Dr Marie Plante NCIC CTG, Cervix Working Group GCIG meeting Belgrade, Oct 10-11, 2009.

Slides:



Advertisements
Similar presentations
Cervical Cancer.
Advertisements

Role of Nodal Irradiation in Breast Cancer
Incorporating Cesium-131 Interstitial Implants into Daily Clinical Practice: How to Make Radiation appear exactly where you want. Jonathan Feddock, MD.
Current Management of the Axilla in Breast Cancer Joint Hospital Surgical Grand Round 25 th July, 2009 Princess Margaret Hospital Law Hang Sze.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital.
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Treatment in Recurrent Cervical Cancer
Sentinel Lymph Node Biopsy in Melanoma
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Sentinel Lymph Node Dissection (SND)
Role of Surgical Trials in Gynaecological Oncology Research Henry Kitchener, University of Manchester ANZGOG, March 2013.
Clinical Utility of Combidex in Various Cancers
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Hot topics in breast radiotherapy Mark Beresford.
©American Society of Clinical Oncology All rights reserved. Reprinted.
Hysterectomy.
GCIG Cervix Committee: Prague 2010 William Small Jr. Satoru Sagae.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
Vulvar Cancer A. Gari MD..
Fertility Sparing in Gynecological Cancers
{ Upper Abdominal Debulking of Gynecologic Malignancies Shaun McKenzie, MD Assistant Professor of Surgery University of Kentucky.
1www.zohrehyousefi.com Less Radical Surgery for Patients with Early-Stage Cervical Cancer Dr.Yousefi Professor Mashhad University of Medical Sciences.
SURGERY FOR NSCLC GREG CHRISTODOULIDES MD, FACS, FCCP, FESTS
In the name of God Isfahan medical school Shahnaz Aram MD.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Dpt. Obstetrics & Gynecology Catholic University - Rome
Endometrial Carcinoma
Management of DCIS KWH Experience Dr. Carmen Ho.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
ACRIN Abdominal Committee ACRIN Gynecologic Committee ACRIN 6671 GOG 0233 UPDATE ACRIN PI: M. ATRI GOG PI: M. GOLD.
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
Histopathological evaluation of lymphatic nodules in cancer of the uterine cervix Coordinators: First Author: Asist. Univ. Dr. Chira Liliana Stud. Bogdan.
Francesco Fanfani Gynecologic Oncology Dpt. Obstetrics & Gynecology Catholic University - Rome Radical trachelectomy in.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Oncology / Dysplasia Unit Royal Women’s Hospital, Carlton, Victoria Do all patients with invasive cervical carcinoma need a radical hysterectomy? Leuven.
Treatment Both primary lesion and potential sites of spread should be treated Surgery, radiotherapy, chemoradiation Radiation therapy can be used in all.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,
Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.
JFM Surgical management of GI and GU endometriosis Javier Magrina, MD Mayo Clinic in Arizona JFM
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Optimal Approaches for Patients With Recurrent or Metastatic Cervical Cancer This program is supported by an educational grant from AstraZeneca.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Surgery As Monotherapy for Wilms’ Tumor Lisly Chéry April 15, 2010.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Management of early stage cervical cancer
ELIGIBILITY CRITERIA- Summarised
Over 1,000 robotic surgeries performed to date, and counting
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Zehra Nihal Dolgun, Ahmet Salih Altintas, Cihan Inan, Petek Balkanli
Surgical Treatment in Locally Advanced Prostate Cancer
Ignace Vergote, MD PhD FACS Voorzitter Leuvens Kanker Instituut (LKI)
Definitive Analysis of the Primary Outcomes
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Pericervical injection of 99mTc-Nanocolloid IS superior to peritumoral injection for sentinel lymph node detection in SPECT/CT Dr. Martin Weiss Department.
بررسی اثرتشخیصی تکنسیوم 99 و متیلن بلو در بررسی گرفتاری گره لنفاوی sentinel در بیماران مبتلا به سرطان اندومتر کم خطر استاد راهنما: سرکار خانم دکترفریبا.
Adjuvant Radiation is Required for Gastric Cancer
KYOTO LACC and beyond David Milliken
Clinical Fellow Gynaeoncology Musgrove Park Hospital, Taunton
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
The role of simultaneous resection of synchronous liver metastasis and primary colorectal cancer Samuel Lo Department of Surgery.
Presentation transcript:

Less Radical Surgery for Patients with Early-Stage Cervical Cancer Dr Marie Plante NCIC CTG, Cervix Working Group GCIG meeting Belgrade, Oct 10-11, 2009

Less Radical Surgery  Rationale  Trial proposal  Areas of controversies

Less radical surgery  Morbidity of the radical hysterectomy and nodes comes from l Lymphadenectomy Lymphocele/lymphoedema, nerve/vessel injury l Parametrectomy Damage to autonomic nerve fibers a/w bladder, bowel and sexual dysfunction Late urological/rectal dysfunctions: 20-30% Magrina 1995, Sood 2002, Benedetti-Panici 2005

Less Radical Surgery  In low risk disease l Stage Ib1 l < 2 cm l LVSI -  Rate of lymph node metastasis: < 5% Kinney WK. Gynecol Oncol 57:3-6, 1995

Less Radical Surgery  Review of 1063 cases of stage IA2 l Rate of lymph node mets: < 5% 12% in ptes with LVSI + 1.3% in ptes with LVSI - l Recurrence rate: 3.6% Van Meurs H et al. Int J Gynecol Cancer 19: 21, 2009

Less Radical Surgery  Review of 1565 cases of IA1/IA2 adenoca l Rate LN mets: 1.5% l Recurrence rate: 2.4% l Cone alone appears to be safe l PLND may be avoided in LVSI - patients Bisseling K and Quinn M. Gynecol Oncol 107: 424, 2007

Less radical surgery  Parametrial invasion (PI) l Retrospective study of 842 ptes l Risk of PI was 0.6% if Tumor size < 2 cm Negative pelvic nodes Depth of stromal invasion < 10 mm Covens et al. Gynecol Oncol 2002; 84: 145

Less radical surgery  Parametrial invasion l Retrospective review of 594 ptes l PI in node + and node - ptes : 48 vs 6% l PI was found in 0.4% if Node negative ptes No LVSI Tumors < 2 cm Wright JD et al. Cancer 2007; 110: 1281

Less radical surgery  Parametrial invasion l Literature review of ptes with low-risk pathological characteristics: Tumor size < 2 cm Stromal invasion < 10 mm Negative pelvic nodes No LVSI l Risk of PI was 0.63% (5/799) Stegeman et al. Gynecol Oncol 2007; 105: 475

Less radical surgery  Hard to justify the morbidity of a radical hysterectomy and parametrectomy in very low risk patients l Risk of PI < 1%  Lymphadenectomy probably still justified although LN mets low < 5% l Could possibly be omitted in IA2/LVSI -

Less radical surgery  Sentinel node mapping l Particularly effective in small lesions (< 2 cm) Detection rate: 100% False negative rate: 0% l Could reduce the radicality/morbidity of the PLND in this low risk group Rob L et al. Gynecol Oncol 98: 281, 2005

Less radical surgery  Relationship between SN vs PI status l 158 ptes IA2/IB1 If SN +: risk of PI 28% If SN - : risk of PI 0% if –Tumor < 2 cm –Stromal invasion < 50% Strnad P et al. Gynecol Oncol 2008; 109: 280

Less radical surgery  Pilot study : n=60 l Procedure Laparoscopic SLN followed by PNLD in SN- ptes on FS and simple vaginal hysterectomy l Selection criteria IA1/VSI (3), IA2 (11), IB1 < 2 cm and SI < 50% (46) Diagnosis by leep/cone (75%) or cx biopsy (25%) MRI after to identify residual disease LVSI not excluded Pluta M et al. Gynecol Oncol 2009; 113: 181

Less radical surgery  Pilot study n=60 l 5 ptes had + SLN (8.3%) 3 detected on FS: rad hyst / nodes + RT 2 missed on FS (micromets); one had RT l Median F/U: 47 mo (12-92) No recurrences Pluta M et al. Gynecol Oncol 2009; 113: 181

Less radical surgery  Pilot study n=60 l « Parametrectomy » Medial part of the lateral parametrium –Between cervical fascia and obliterated umbilical artery Resection of parametrial « blue node » with ex-vivo radioactive count and parametrial « blue channels » Pluta M et al. Gynecol Oncol 2009; 113: 181

Parametrial SN Right obturator SNRight parametrial SN Ureter uterine artery Sup. vesical arteryObturator nerve

Less radical surgery  Proposed protocol

Proposed Protocol

Less radical surgery  Study design: randomized trial l Modified rad hyst/nodes vs. simple hyst/nodes Outcome primary endpoint: 1500 ptes (80% power to show a difference of 2% in pelvic relapse, i.e, 2 vs 4%) Toxicity primary endpoint: 320 ptes *** (favoured) (80% power to show a difference of 10% in acute severe toxicity, i.e, 15 vs 5%) l A prospective cohort to be compared with similar sized contemporaneous cohort of ptes treated by rad hyst: 160 ptes (least favoured)

Less radical surgery  Study design l Modified rad hyst/nodes vs. simple hyst/nodes Toxicity primary endpoint: 320 ptes (80% power to show a difference of 10% in acute severe toxicity, i.e, 15 vs 5%) Expected to be primarily bladder complications, with smaller numbers of post-operative and operative events (infection, bleeding, thromboembolic etc.) Early stopping if relapse in the experimental arm exceeds an agreed upon threshold (e.g. more than 4%, stats pending)

Less radical surgery  Question l Would more limited surgery reduce morbidity without jeopardizing outcome  Objective l Feasibility/safety of less radical surgery l Oncologic outcome and treatment-related morbidity  Inclusion criteria l Stage IA1/LVSI, IA2- IB1 < 2 cm with < 50% SI l Adeno and squamous l All grades l LVSI

Less radical surgery  Primary endpoints l Operative morbidity l Severe toxicity (< 12 months)  Secondary endpoints l SLN detection rate l Rates of PI, positive SLN, positive margins l Relapse (site) and survival l QoL (NCI-CTC version 3)

Less radical surgery  Points of discussion l Imaging requirement Pelvic MRI ? l Sentinel node mapping « parametrial node » resection. Is it reproducible ? l Stratification IA2 vs IB1 With/without LVSI Surgical approach (abdominal vs vaginal/laparoscopic/robotic)

Less radical surgery  Points of discussion l Exclusion criteria IA1 with LVSI If not doing nodes in stage IA2 and LVSI- Cone alone for fertility preservation –Can’t really compare morbidity of rad hyst vs. cone l Central pathology review ? Diagnostic cone/LEEP mandatory to assess depth of stromal invasion and size ? Do we consider depth of stromal invasion or not

MD Anderson Trial  Prospective multi-institutional trial l MSKCC l Texas (El Paso) l Czech Republic (2 centers) l Colombia  Sample size l cases Schmeler Kathleen et al

MD Anderson Trial  Criteria differ l IA1 (VSI) excluded l Grade 3 adenoca excluded l LVSI excluded l Diagnostic cone/ECC with negative margins for cancer or ACIS If +, 2nd cone allowed l Inclusion of women who wish to preserve fertility SN and PLND only Schmeler Kathleen et al

MD Anderson Trial  Objectives: l Safety, feasibility, recurrence at 2 years l Nodal involvement and tx-related morbidity compared to historical data from matched patients treated with rad hyst l QoL (5 questionnaires !)

Pluta M et al. Gynecol Oncol 2009; 113: 181 Prague protocol